BRCA2 and CDKN1A Interacting Protein (BCCIP) (AA 139-260) antibody
|Synonyms||TOK1, TOK-1, 1110013J05Rik, BCCIP, MGC134343, zgc:110272, mp:zf637-1-000774, DKFZp459K2416, MGC82792, tok-1, MGC89311|
Alternatives Western Blotting (WB), Immunofluorescence (IF)
|2 references available|
|Quantity||50 µg (250 µg/ml)|
|Price||Product not available in this region.|
|Cross-Reactivity||Mouse (Murine), Rat (Rattus)|
|Description||Cell cycle progression is tightly regulated by the actions of cyclins and cyclin dependent kinases (Cdks). p21 forms a quaternary complex that includes Cyclin D, Cdk4, and PCNA, and is induced during p53-dependent and -independent responses to cellular stress. p21 promotes cell cycle arrest by preventing the phosphorylation and activation of Cdk. Although the Cdks are inhibited via direct interaction with the N-terminal region of p21, various other proteins bind the C-terminal region. TOK-1 is a p21 interacting protein that exists as 50 kDa (TOK-1alpha) and 45 kDa (TOK-1ß) isoforms. While both isoforms are primarily expressed in skeletal muscle, TOK-1ß is also expressed in a variety of other tissues, including placenta and pancreas. Although both isoforms localize to the nucleus, TOK-1alpha, not TOK-1ß, is coexpressed with p21 at the G1/S boundary and directly binds the C-terminal region of p21. TOK-1alpha has been shown to enhance the activity of p21,which inhibits the H1 kinase activity of Cdk2. In addition, the TOK proteins were identified as BCCIPalpha and BCCIPß, which are nuclear proteins that interact with BRCA2 and function in tumor suppression. Therefore, TOK-1 proteins may regulate cell cycle dynamics and cell transformation through a variety of protein-protein interactions.|
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Please refer to us for technical protocols.
|Molecular Weight||45/50 kDa|
Related Products: ABIN968535, ABIN967389
|Purification||Purified from tissue culture supernatant or ascites by affinity chromatography.|
|Buffer||Aqueous buffered solution containing BSA, glycerol.|
|Preservative||0.09% Sodium azide.|
|Storage||Store undiluted at -20° C.|
|Restrictions||For Research Use only|
|Western blot analysis of TOK-1 on a HeLa cell lysate (Human cervical epitheloid carcinoma, ATCC CCL-2). Lane 1: 1:1000, lane 2: 1:2000, lane 3: 1:4000 dilution of the Mouse Anti-TOK-1 antibody. Immunofluorescence staining of HeLa cells.|
Ono, Kitaura, Ugai et al.: "TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase." in: The Journal of biological chemistry, Vol. 275, Issue 40, pp. 31145-54, 2000 (PubMed).
Liu, Yuan, Huan et al.: "Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2." in: Oncogene, Vol. 20, Issue 3, pp. 336-45, 2001 (PubMed).
|Hosts||Rabbit (28), Mouse (2)|
|Reactivities||Human (30), Mouse (Murine) (4), Rat (Rattus) (3), Cat (Feline) (1), Chicken (1), Cow (Bovine) (1), Dog (Canine) (1)|
|Applications||Immunofluorescence (IF) (15), Western Blotting (WB) (14), ELISA (13), Immunohistochemistry (Formalin-fixed Sections) (IHC (f)) (2), Immunohistochemistry (IHC) (2), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) (2), Dot Blot (Dot) (1), Immunoelectron Microscopy (IEM) (1), Immunoprecipitation (IP) (1)|
|Conjugates||Alexa Fluor 350 (1), Alexa Fluor 488 (1), Alexa Fluor 555 (1), Alexa Fluor 647 (1), Biotin (1), Cy3 (1), Cy5 (1), Cy5.5 (1), Cy7 (1), FITC (1), Gold (1), HRP (1), PE (1), PE,Cy3 (1), PE,Cy5 (1), PE,Cy5.5 (1), PE,Cy7 (1)|
|Epitopes||C-Term (3), Center (1), Internal Region (1)|